These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
216 related items for PubMed ID: 15955621
1. Thioredoxin reductase as a novel molecular target for cancer therapy. Nguyen P, Awwad RT, Smart DD, Spitz DR, Gius D. Cancer Lett; 2006 May 18; 236(2):164-74. PubMed ID: 15955621 [Abstract] [Full Text] [Related]
2. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, Karra S, Bradbury CM, Markovina S, Goswami PC, Spitz DR, Hirota K, Kalvakolanu DV, Yodoi J, Gius D. Oncogene; 2002 Sep 12; 21(41):6317-27. PubMed ID: 12214272 [Abstract] [Full Text] [Related]
3. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, Gius D. Drug Resist Updat; 2005 Oct 12; 8(5):322-30. PubMed ID: 16230045 [Abstract] [Full Text] [Related]
4. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. Anticancer Res; 2003 Oct 12; 23(3B):2425-33. PubMed ID: 12894524 [Abstract] [Full Text] [Related]
5. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Smart DK, Ortiz KL, Mattson D, Bradbury CM, Bisht KS, Sieck LK, Brechbiel MW, Gius D. Cancer Res; 2004 Sep 15; 64(18):6716-24. PubMed ID: 15374989 [Abstract] [Full Text] [Related]
6. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D. Curr Pharm Des; 2007 Sep 15; 13(33):3368-77. PubMed ID: 18045191 [Abstract] [Full Text] [Related]
10. On the potential of thioredoxin reductase inhibitors for cancer therapy. Urig S, Becker K. Semin Cancer Biol; 2006 Dec 15; 16(6):452-65. PubMed ID: 17056271 [Abstract] [Full Text] [Related]
12. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Engman L, Cotgreave I, Angulo M, Taylor CW, Paine-Murrieta GD, Powis G. Anticancer Res; 1997 Dec 15; 17(6D):4599-605. PubMed ID: 9494575 [Abstract] [Full Text] [Related]
13. Selenium and the thioredoxin redox system: effects on cell growth and death. Powis G, Gasdaska JR, Gasdaska PY, Berggren M, Kirkpatrick DL, Engman L, Cotgreave IA, Angulo M, Baker A. Oncol Res; 1997 Dec 15; 9(6-7):303-12. PubMed ID: 9406236 [Abstract] [Full Text] [Related]
14. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity. Liu Z, Huang SL, Li MM, Huang ZS, Lee KS, Gu LQ. Chem Biol Interact; 2009 Jan 15; 177(1):48-57. PubMed ID: 18822278 [Abstract] [Full Text] [Related]
15. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Wang X, Zhang J, Xu T. Eur J Pharmacol; 2008 Jan 28; 579(1-3):66-73. PubMed ID: 18028906 [Abstract] [Full Text] [Related]
18. Redox active disulfides: the thioredoxin system as a drug target. Kirkpatrick DL, Ehrmantraut G, Stettner S, Kunkel M, Powis G. Oncol Res; 1997 Jan 28; 9(6-7):351-6. PubMed ID: 9406241 [Abstract] [Full Text] [Related]
19. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Wang X, Zhang J, Xu T. Toxicol Appl Pharmacol; 2007 Jan 01; 218(1):88-95. PubMed ID: 17156807 [Abstract] [Full Text] [Related]
20. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. Wipf P, Lynch SM, Powis G, Birmingham A, Englund EE. Org Biomol Chem; 2005 Nov 07; 3(21):3880-2. PubMed ID: 16240002 [Abstract] [Full Text] [Related] Page: [Next] [New Search]